drugset / Trial / NCT00666458

18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)

NCT00666458

Phase 3 Completed 822 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin in addition with metformin.

Timeline

Start
2008-04
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule Oral
Comparator Sitagliptin Small molecule Oral